Arvinas Inc. (ARVN) and Pfizer (PFE) Announce PROTAC Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breas

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Arvinas Inc. (ARVN) and Pfizer (PFE) Announce PROTAC Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breas

Low Valuations to Drive Pharma M&A in 2022 - Analyst

December 13, 2021 8:50 AM EST

In light of recently announced major biotech acquisitions - Dicerna (NASDAQ: DRNA) was acquired by Novo Nordisk (NYSE: NVO) for $38 (~80% premium) and Arena (NASDAQ: ARNA) now being acquired for $100/sh (~100% premium) by Pfizer... More

Pfizer (PFE) Raises Quarterly Dividend 2.6% to $0.40; 3% Yield

December 10, 2021 12:01 PM EST

Pfizer (NYSE: PFE) declared a quarterly dividend of $0.40 per share, or $1.6 annualized. This is a 2.6% increase from the prior dividend of $0.39.

The dividend will be payable on March 4, 2022, to stockholders of record on January 28, 2022, with an ex-dividend date of January 27,... More

Pfizer's (PFE) Cibinqo Approved in EU for Treatment of Adults with Moderate-to-Severe Atopic Dermatitis

December 10, 2021 9:27 AM EST

Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved the 100 mg and 200 mg doses of Cibinqo® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy. Additionally, a 50 mg dose was approved to treat moderate-to-severe AD specifically in... More